AUTHOR AND EDITOR INFORMATION

Section 1 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

INTRODUCTION

Section 2 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Background

Foot infections are the most common problems in persons with diabetes. These individuals are predisposed to foot infections because of a compromised vascular supply secondary to diabetes. Local trauma and/or pressure (often in association with lack of sensation because of neuropathy), in addition to microvascular disease, may result in various diabetic foot infections. For additional information, see Medscape’s Diabetic Microvascular Complications Resource Center.

The spectrum of foot infections in diabetes ranges from simple superficial cellulitis to chronic osteomyelitis. Infections in patients with diabetes are difficult to treat because these patients have impaired microvascular circulation, which limits the access of phagocytic cells to the infected area and results in a poor concentration of antibiotics in the infected tissues. For this reason, cellulitis is the most easily treatable and reversible form of foot infections in patients with diabetes. Deep skin and soft tissue infections are also usually curable, but they can be life threatening and result in substantial long-term morbidity.

In terms of the infecting microorganisms and the likelihood of successful treatment with antimicrobial therapy, acute osteomyelitis in people with diabetes is essentially the same as in those without diabetes. Chronic osteomyelitis in patients with diabetes mellitus is the most difficult infection to cure. Adequate surgical debridement, in addition to antimicrobial therapy, is necessary to cure chronic osteomyelitis.

Patients with diabetes also can have a combined infection involving bone and soft tissue called fetid foot. This extensive, chronic soft tissue and bone infection causes a foul exudate and usually requires extensive surgical debridement and/or amputation.

Individuals with diabetes may also have peripheral vascular disease that involves the large vessels, in addition to microvascular and capillary disease that results in peripheral vascular disease with gangrene. Dry gangrene is usually managed with expectant care, and gross infection is usually not present. Wet gangrene usually has an infectious component and requires surgical debridement and/or antimicrobial therapy to control the infection.

Except for chronic osteomyelitis, infections in patients with diabetes are caused by the same microorganisms that can infect the extremities of those without diabetes. Gas gangrene is conspicuous because of its low incidence in patients with diabetes, but deep skin and soft tissue infections, which are due to gas-producing organisms, frequently occur in patients with diabetes. In general, people with diabetes have infections that are more severe and take longer to cure than equivalent infections in other people.

Pathophysiology

Diabetes mellitus is a disorder that primarily affects the microvascular circulation. In the extremities, microvascular disease due to "sugar-coated capillaries" limits the blood supply to the superficial and deep structures. Pressure due to ill-fitting shoes or trauma further compromises the local blood supply at the microvascular level, predisposing the patient to infection. The infection may involve the skin, soft tissues, bone, or all of these tissues.

Diabetes also accelerates macrovascular disease, which is evident clinically as accelerating atherosclerosis and/or peripheral vascular disease. Most diabetic foot infections occur in the setting of good dorsalis pedis pulses; this finding indicates that the primary problem in diabetic foot infections is microvascular compromise. Impaired microvascular circulation hinders white cell migration into the area of infection and limits the ability of antibiotics to reach the site of infection in an effective concentration. Diabetic neuropathy may be encountered in conjunction with vasculopathy. This may allow for incidental trauma that goes unrecognized (eg, blistering, penetrating foreign body).

In chronic osteomyelitis, a sequestrum and involucrum form; these represent islands of infected bone. Bone fragments that are isolated have no blood supply. Administered antibiotics do not penetrate the devascularized infected bone fragments; they can enter the area of osteomyelitis only via the remaining blood supply. Therefore, antibiotic therapy alone cannot cure patients with chronic osteomyelitis without surgical debridement to remove these isolated infected elements. Surgical debridement is essential to remove the infected bony fragments that the antibiotics cannot reach so that affected areas can be treated with antimicrobial therapy.

Frequency

International

Diabetic foot infections range from cellulitis to chronic osteomyelitis, and, globally, they are the most common skeletal and soft tissue infections in patients with diabetes.

Mortality/Morbidity

Mortality is not common, except in unusual circumstances. The mortality risk is highest in patients with chronic osteomyelitis and in those with acute necrotizing soft tissue infections.

Race

The incidence of diabetic foot infections is similar to that of diabetes in various ethnic groups.

Sex

No important sex differences exist.

Age

Diabetic foot infections most frequently affect elderly patients.

CLINICAL

Section 3 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

History

Patients may or may not have a history of trauma or previous infection.

Physical

Findings after physical examination may include the following:

• Cellulitis
• • Cellulitis may involve tender and erythematous nonraised skin lesions on the lower extremity that may or may not be accompanied by lymphangitis.
  • Lymphangitis suggests a group A streptococcal etiology.
  • If bullae are present, Staphylococcus aureus is the most likely pathogen, but group A streptococci occasionally causes bullous lesions.
  • No ulcer or wound exudate is present in patients with cellulitis.
• Deep skin and soft tissue infections
• • Patients with deep skin and soft tissue infections may be acutely ill, with painful induration of the soft tissues in the extremity.
  • These infections are particularly common in the thigh area, but they may be seen anywhere on the leg or foot.
  • Wound discharge is usually not present. In mixed infections that may involve anaerobes, crepitation may be noted over the afflicted area.
  • Extreme pain and tenderness indicate the possibility of a compartment syndrome, which may be diagnosed with the aid of a CT scan. Similarly, extreme pain may be an indication of infection with clostridial species (ie, gas gangrene).
  • The tissues are not tense, and bullae may be present.
  • If a discharge is present, it is often foul.
• Acute osteomyelitis
• • Unless peripheral neuropathy is present, the patient has pain at the site of the involved bone.
  • Usually, fever and regional adenopathy are absent.
• Chronic osteomyelitis
• • In chronic osteomyelitis, the patient's temperature is usually less than 102°F.
  • Discharge is commonly foul.
  • No lymphangitis is observed.
  • Pain may or may not be present, depending on the degree of peripheral neuropathy.
  • The deep penetrating ulcers and sinuses are usually located between the toes or on the plantar surface of the foot.
  • In patients with diabetes, chronic osteomyelitis usually does not occur on the medial malleoli, shins, or heels.
  • Importantly, deep penetrating foot ulcers or deep sinus tracts are diagnostic of chronic osteomyelitis.

Causes

The microbiologic features of diabetic foot infections vary according to the tissue infected.

• In patients with diabetes, superficial skin infections such as cellulitis are caused by the same organisms as those in healthy hosts, namely group A streptococci and S aureus. However, in unusual epidemiologic circumstances, organisms such as Pasteurella multocida (eg, from dog or cat bites or scratches) may be noted and should always be considered.
• Group B streptococcal cellulitis is uncommon in healthy hosts and not uncommon in patients with diabetes. In people with diabetes, group B streptococci may cause urinary tract infections and catheter-associated bacteriuria in addition to cellulitis, skin and/or soft tissue infections, and chronic osteomyelitis. Such infections may be complicated by bacteremia.
• In patients with diabetes, deep soft tissue infections can be associated with gas-producing gram-negative bacilli. Clinically, these infections appear as necrotizing fasciitis, compartment syndrome, or myositis. Gas gangrene is uncommon in persons with diabetes.
• Acute osteomyelitis usually occurs as a result of foot trauma in an individual with diabetes. The distribution of organisms is the same as in an individual without diabetes who has acute osteomyelitis.
• In chronic osteomyelitis, the pathogens are group A and group B streptococci, aerobic gram-negative bacilli, and Bacteroides fragilis, among others.
• • Pseudomonas aeruginosa is generally not a pathogen in chronic osteomyelitis in patients with diabetes.
  • P aeruginosa is frequently cultured from samples obtained from a draining sinus tract or deep penetrating ulcers in patients with diabetes. However, these organisms are superficial colonizers and are generally not the cause of the bone infection.
  • Because Pseudomonas organisms are water-borne, superficial ulcers may be contaminated by bacteria in wet socks or dressings. To the author's knowledge, no well-documented cases of biopsy-proven P aeruginosa infection have been reported in patients with chronic osteomyelitis.
  • Bone biopsy performed under aseptic conditions in the operating room reveals that chronic osteomyelitis in patients with diabetes is not due to P aeruginosa.
  • B fragilis is an important bone pathogen in chronic osteomyelitis in patients with diabetes.
  • Other pathogens implicated in chronic osteomyelitis in patients with diabetes include Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.
• Fetid foot represents a combined deep skin and soft tissue infection caused by pathogens involved in chronic osteomyelitis.

DIFFERENTIALS

Section 4 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Other Problems to be Considered

Cellulitis - Leukoclastic angitis, diabetic dermopathy, chronic venostatic change, superficial thrombophlebitis

Deep skin and soft tissue infections - Gas gangrene, synergistic gangrene, Vibrio vulnificus infection, Aeromonas hydrophilia infection

Acute osteomyelitis - Sickle cell crisis, Lyme arthritis, sarcoid arthritis, blunt bone trauma, bone tumor

Chronic osteomyelitis - Squamous cell carcinoma, bone tumor, neuropathic joint

WORKUP

Section 5 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Lab Studies

• Cellulitis
• • The CBC count and erythrocyte sedimentation rate (ESR) are slightly or moderately elevated in cellulitis. Elevations are not diagnostic and, therefore, are unhelpful.
  • Blood culture results are usually negative. If positive, they usually indicate the presence of group A or group B streptococci. Cultures of skin via aspiration or biopsy are generally unrewarding.
• Skin and soft tissue infections
• • The CBC count and ESR are mildly or moderately elevated.
  • If bullae are present, Gram stain and culture results in aspirated exudate from a bullous lesion may provide clues to the etiology of the infection.
  • Blood culture results may be positive.
• Acute osteomyelitis
• • The CBC count usually reveals leukocytosis, and the ESR is moderately or highly elevated.¹
  • Blood culture results are usually negative. When positive, the findings most frequently indicate the presence of S aureus.
• Chronic osteomyelitis
• • The CBC count is often within the reference range. Usually, the ESR is very highly elevated; it may exceed 100 mm/h.¹
  • The platelet count is often elevated in chronic osteomyelitis.
  • Blood culture results are usually negative in patients with chronic osteomyelitis.

Imaging Studies

• Cellulitis: Image studies are not applicable.
• Deep skin and soft tissue infections
• • In a patient with diabetes considered to have a deep soft tissue infection, plain radiography, CT scan, or MRI may be performed to rule out a compartment syndrome and to demonstrate the presence of gas or a foreign body in the deep tissues.
  • A finding of excessive gas signifies a mixed aerobic-anaerobic infection in contrast to gas gangrene (clostridial myonecrosis).
• Acute osteomyelitis
• • For long bones, plain radiographic findings generally become abnormal after 10-14 days. Soft tissue swelling and periosteal elevation are the earliest signs of acute osteomyelitis on a plain radiograph.
  • Bone scan findings are positive within 24 hours in acute osteomyelitis.
  • A bone scan is preferred to gallium or indium scans in the assessment of acute osteomyelitis.
  • Gallium or indium scans offer no additional information, and the findings are not more specific than those of bone scans in the diagnosis of osteomyelitis.
  • Indium scans often show false-negative results in acute or chronic osteomyelitis.
• Chronic osteomyelitis
• • When osteomyelitis becomes chronic, plain radiographic findings are invariably abnormal.
  • Bone scans are usually unnecessary unless diagnostic confusion exists with another disorder.
  • A bone tumor is best differentiated from chronic osteomyelitis with the aid of bone scanning or MRI prior to definitive bone biopsy.

Other Tests

• Patients with diabetic foot infections and peripheral vascular disease may benefit from vascular surgical evaluation to bypass large-vessel occlusive disease. However, large-vessel bypass does not cure the microvascular component of diabetic foot infections.

Procedures

• Aspiration of a sample from the leading edge of the erythematous border in a patient with cellulitis is usually not necessary, but a sample may be aspirated if the likely organism must be identified on initial presentation. However, the yield is low, likely to be less than 5%.
• Samples from deep skin and soft tissue infections may be aspirated. Gram stains and/or cultures may be used to identify the organism.
• Aside from blood culturing, radiography, and nuclear imaging studies, bone biopsy is not necessary in acute osteomyelitis because the pathogens are predictable.
• Bone biopsy performed under aseptic conditions in the operating room is the preferred way to identify the causative pathogen in chronic osteomyelitis. Because surgical debridement is critical in treating chronic osteomyelitis, bone biopsy specimens are usually not obtained during the surgical debridement procedure.

Histologic Findings

Involucrum and/or sequestrum may be present in the cortical bone in cases of chronic osteomyelitis. Subperiosteal elevation and/or infection may involve the cortex in acute osteomyelitis.

Staging

Staging is applicable only in cases of chronic osteomyelitis that require surgery.

TREATMENT

Section 6 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Medical Care

Immobilization is important in acute or chronic osteomyelitis.

Surgical Care

Chronic osteomyelitis cannot be cured without adequate surgical debridement.

Consultations

• Appropriate consultation with a surgeon should be obtained for debridement and/or amputation in chronic osteomyelitis.
• A general or vascular surgeon should be consulted for the debridement or decompression of compartment syndromes in patients with deep skin and soft tissue infections.
• An infectious disease specialist should be consulted in the treatment of all patients with diabetic foot infections to optimize the antimicrobial therapy.

Diet

Dietary modifications are not applicable except to optimize diabetes control.

Activity

The patient may participate in activities as tolerated. However, weight-bearing may be contraindicated.

MEDICATION

Section 7 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

In patients with diabetes, cellulitis is generally caused by group A and group B streptococci and, occasionally, S aureus. Cellulitis may be treated with single antibiotics that have the appropriate spectrum or with combination therapy that covers the appropriate organisms.

Drug Category: Antibiotics

Appropriate monotherapy for cellulitis includes cefazolin or clindamycin. Although gram-negative organisms are the unusual causes of cellulitis, even in diabetes, if they are suspected, a fluoroquinolone (eg, levofloxacin) may be used in conjunction with clindamycin.

In patients with diabetes, deep skin and severe soft tissue infections are usually due to mixed aerobic and anaerobic organisms. These infections may be treated with monotherapy involving meropenem or piperacillin and tazobactam. Alternatively, clindamycin plus levofloxacin or metronidazole may be used.

Acute osteomyelitis, which usually is due to S aureus, may be treated with cefazolin, clindamycin, and an antistaphylococcal penicillin (eg, nafcillin).

In chronic osteomyelitis, coverage must be directed against S aureus, group A and group B streptococci, aerobic gram-negative bacilli (excluding P aeruginosa), and B fragilis. Monotherapy for chronic osteomyelitis may include ampicillin and sulbactam, piperacillin and tazobactam, or meropenem. In chronic osteomyelitis, antimicrobial therapy without adequate debridement does not eliminate the infection.

Combination therapy for diabetic foot infections involves levofloxacin plus clindamycin.

FOLLOW-UP

Section 8 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Further Inpatient Care

• Surgical debridement in chronic osteomyelitis is the most important therapeutic intervention. Chronic osteomyelitis cannot be cured without adequate surgical debridement. In some cases, amputation is required.
• If amputation is performed, physical therapy and rehabilitation may be started on an inpatient basis and completed on an outpatient basis.

Further Outpatient Care

• Cellulitis: No further care is necessary.
• Skin and soft tissue infection: Additional debridement generally is indicated. If the foot is involved, the best care plan is aggressive therapy to avoid surgery beyond transmetatarsal amputation, ie, limit surgical extirpation to the forefoot.
• Acute osteomyelitis: Monitor the patient's condition to ensure that the infection has resolved.
• Chronic osteomyelitis: Ensure that debridement is complete and that no further remnants of infected bone remain.

In/Out Patient Meds

• Cellulitis, skin and soft tissue infections, acute osteomyelitis, and chronic osteomyelitis may be treated with oral medications in an outpatient setting on a case-by-case basis.
• If oral antibiotic therapy with excellent bioavailability is selected, it is equivalent to intravenous therapy. Therefore, home intravenous therapy for osteomyelitis is seldom needed. For virtually all infecting organisms, even those that are highly resistant, numerous oral antibiotics can be used in place of intravenous antibiotics.
• In chronic osteomyelitis, neither oral nor intravenous medications are effective without adequate surgical debridement.

Deterrence/Prevention

• Patients with diabetes must be careful to avoid foot trauma and to properly care for their feet to minimize the possibility of infection.

Complications

• Bacteremia may accompany cellulitis, skin or soft tissue infections, and/or acute osteomyelitis, but these are not complications per se.
• If chronic osteomyelitis is left untreated for years, it may lead to complications such as amyloidosis or squamous cell carcinoma at the site of drainage through the skin.
• Bacteremia and septic shock rarely, if ever, occur as a result of chronic osteomyelitis.

Prognosis

• The prognosis for cases of cellulitis, skin and/or soft tissue infections, or acute osteomyelitis depends on the adequacy of antimicrobial therapy and surgical debridement, as indicated.
• For cases of chronic osteomyelitis, the prognosis is directly related to the vascular supply in the affected limb and the adequacy of surgical debridement.

Patient Education

• Patients must understand that chronic osteomyelitis cannot be cured with antibiotics alone and that adequate surgical debridement is necessary.
• Patients who are unwilling to undergo the surgical procedure must understand the long-term complications of chronic osteomyelitis. Long-term suppressive therapy may decrease the incidence of septic complications, but it does not affect the long-term complications, which may include amyloidosis or squamous cell carcinoma at the drainage site.
• For excellent patient education resources, visit eMedicine's Diabetes Center. Also, see eMedicine's patient education article, Diabetic Foot Care.

MISCELLANEOUS

Section 9 of 10  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

Medical/Legal Pitfalls

• Patients with chronic osteomyelitis should be advised that, if the infection is not adequately treated with sufficient surgical debridement and/or amputation, systemic complications may occur over time.
• Possible systemic complications include bacteremia and/or systemic infection, amyloidosis, and squamous cell carcinoma at the affected site.

REFERENCES

Section 10 of 10

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• References

1. Malabu UH, Al-Rubeaan KA, Al-Derewish M. Diabetic foot osteomyelitis: usefulness of erythrocyte sedimentation rate in its diagnosis. West Afr J Med. Apr-Jun 2007;26(2):113-6. [Medline].
2. Andersen CA, Roukis TS. The diabetic foot. Surg Clin North Am. Oct 2007;87(5):1149-77, x. [Medline].
3. Armstrong DG, Lanthier J, Lelievre P, Edelson GW. Methicillin-resistant coagulase-negative staphylococcal osteomyelitis and its relationship to broad-spectrum oral antibiosis in a predominantly diabetic population. J Foot Ankle Surg. Nov-Dec 1995;34(6):563-6. [Medline].
4. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care. May 1998;21(5):855-9. [Medline].
5. Bridges RM Jr, Deitch EA. Diabetic foot infections. Pathophysiology and treatment. Surg Clin North Am. Jun 1994;74(3):537-55. [Medline].
6. Caputo GM, Joshi N, Weitekamp MR. Foot infections in patients with diabetes. Am Fam Physician. Jul 1997;56(1):195-202. [Medline].
7. Cunha BA. Antibiotic Essentials. 7th Ed. Royal Oak, MI: Physicians Press; 2008.
8. Cunha BA. Antibiotic selection for diabetic foot infections: a review. J Foot Ankle Surg. Jul-Aug 2000;39(4):253-7. [Medline].
9. Cunha BA. Diabetic foot infections. Emerg Med. 1997;10:115-24.
10. Cunha BA. Skin and soft tissue infections in patients with diabetes mellitus. Infect Dis Pract. 1997;10:94-5.
11. Day MR, Armstrong DG. Factors associated with methicillin resistance in diabetic foot infections. J Foot Ankle Surg. Jul-Aug 1997;36(4):322-5; discussion 331. [Medline].
12. Diamantopoulos EJ, Haritos D, Yfandi G, Grigoriadou M, Margariti G, Paniara O, et al. Management and outcome of severe diabetic foot infections. Exp Clin Endocrinol Diabetes. 1998;106(4):346-52. [Medline].
13. Edelson GW, Armstrong DG, Lavery LA, Caicco G. The acutely infected diabetic foot is not adequately evaluated in an inpatient setting. J Am Podiatr Med Assoc. Jun 1997;87(6):260-5. [Medline].
14. Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Nakeeb A, Cambria RA, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother. Mar 2004;48(3):1012-6. [Medline].
15. Gleckman RA, Roth RM. Diabetic foot infections--prevention and treatment. West J Med. Feb 1985;142(2):263-5. [Medline].
16. Goldstein EJ, Citron DM, Nesbit CA. Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care. Jun 1996;19(6):638-41. [Medline].
17. Grayson ML. Diabetic foot infections. Antimicrobial therapy. Infect Dis Clin North Am. Mar 1995;9(1):143-61. [Medline].
18. Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA. Mar 1 1995;273(9):721-3. [Medline].
19. Koutkia P, Mylonakis E, Boyce J. Cellulitis: evaluation of possible predisposing factors in hospitalized patients. Diagn Microbiol Infect Dis. Aug 1999;34(4):325-7. [Medline].
20. Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis. Aug 1 2004;39 Suppl 2:S104-14. [Medline].
21. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. Nov 12 2005;366(9498):1695-703. [Medline].
22. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. Oct 1 2004;39(7):885-910. [Medline].
23. Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother. Aug 2007;60(2):370-6. [Medline].
24. Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med. Apr 1990;150(4):790-7. [Medline].
25. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. Feb 2005;55(2):240-5. [Medline].
26. Morales WJ, Dickey SS, Bornick P, Lim DV. Change in antibiotic resistance of group B streptococcus: impact on intrapartum management. Am J Obstet Gynecol. Aug 1999;181(2):310-4. [Medline].
27. Perencevich EN, Kaye KD, Strausbaugh LJ. Acceptable rates of treatment failure in osteomyelitis involving the diabetic foot: A survey of infectious diseases consultants. CID. 2004;38:476-482.
28. Rathur HM, Boulton AJ. The diabetic foot. Clin Dermatol. Jan-Feb 2007;25(1):109-20. [Medline].
29. Reiber GE. The epidemiology of diabetic foot problems. Diabet Med. 1996;13 Suppl 1:S6-11. [Medline].
30. Sapico FL, Canawati HN, Witte JL, Montgomerie JZ, Wagner FW Jr, Bessman AN. Quantitative aerobic and anaerobic bacteriology of infected diabetic feet. J Clin Microbiol. Sep 1980;12(3):413-20. [Medline].
31. Senneville E. Antimicrobial interventions for the management of diabetic foot infections. Expert Opin Pharmacother. Feb 2005;6(2):263-73. [Medline].
32. Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother. Oct 2007;60(4):819-23. [Medline].
33. Tan JS. Foot Infections in Diabetic Patients. Curr Infect Dis Rep. Oct 2004;6(5):377-379. [Medline].
34. Tan PL, Teh J. MRI of the diabetic foot: differentiation of infection from neuropathic change. Br J Radiol. Nov 2007;80(959):939-48. [Medline].
35. Wang S, Cunha BA, Hamid NS, Amato BM, Feuerman M, Malone B. Metronidazole single versus multiple daily dosing in serious intraabdominal/pelvic and diabetic foot infections. J Chemother. Aug 2007;19(4):410-6. [Medline].
36. West NJ. Systemic antimicrobial treatment of foot infections in diabetic patients. Am J Health Syst Pharm. Jun 1 1995;52(11):1199-207; quiz 1239-40. [Medline].
37. Wheat LJ, Allen SD, Henry M, Kernek CB, Siders JA, Kuebler T, et al. Diabetic foot infections. Bacteriologic analysis. Arch Intern Med. Oct 1986;146(10):1935-40. [Medline].
38. Zgonis T, Roukis TS. A systematic approach to diabetic foot infections. Adv Ther. May-Jun 2005;22(3):244-62. [Medline].

Article Last Updated: Jun 23, 2008